Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vir Biotechnology Inc. (VIR)

35.74   -2.96 (-7.65%) 01-19 08:48
Open: 37.77 Pre. Close: 38.7
High: 37.81 Low: 35.5
Volume: 1,306,038 Market Cap: 4,678M
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 37.845 - 38.029 38.029 - 38.187
Low: 35.079 - 35.282 35.282 - 35.457
Close: 35.437 - 35.751 35.751 - 36.021

Technical analysis

as of: 2022-01-19 8:25:18 AM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 56.23     One year: 67.74
Support: Support1: 32.20    Support2: 26.79
Resistance: Resistance1: 48.14    Resistance2: 58.00
Pivot: 37.03
Moving Average: MA(5): 37.57     MA(20): 38.15
MA(100): 40.90     MA(250): 45.51
MACD: MACD(12,26): -1.46     Signal(9): -1.30
Stochastic oscillator: %K(14,3): 43.78     %D(3): 49.85
RSI: RSI(14): 43.62
52-week: High: 141.01  Low: 29.50  Change(%): -19.5
Average Vol(K): 3-Month: 173927  10-Days: 176372

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
VIR has closed above bottom band by 38.1%. Bollinger Bands are 21.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 19 Jan 2022
Vir Biotechnology, Inc. (NASDAQ:VIR) Sees Significant Decrease in Short Interest - MarketBeat

Fri, 14 Jan 2022
Virtual JPM conference had lots of news — just not a splash - San Francisco Business Times - San Francisco Business Times

Fri, 14 Jan 2022
JPM Day 4: Battered Emergent Solutions Looks Ahead, Vir and Thermo Fisher - BioSpace

Thu, 13 Jan 2022
Thinking about trading options or stock in KB Home, Vir Biotechnology, Applied Materials, Take-Two Interactive, or Nio? - marketscreener.com

Thu, 13 Jan 2022
Vir Biotechnology Launches New Antibody Research Initiative - GlobeNewswire

Tue, 11 Jan 2022
GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19 - GSK

Financial Analysis

Growth n/a
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 131
Shares Float (M) 74
% Held by Insiders 13.16
% Held by Institutions 72.19
Shares Short (K) 3,890
Shares Short P. Month (K) 5,520

Stock Financials

EPS -0.800
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 6.700
Profit Margin -35.98
Operating Margin -61.79
Return on Assets (ttm) -10.2
Return on Equity (ttm) -12.1
Qtrly Rev. Growth 5274.3
Gross Profit (p.s.) -1.501
Sales Per Share 2.173
EBITDA (p.s.) -1.303
Qtrly Earnings Growth
Operating Cash Flow (M) -137
Levered Free Cash Flow (M) 7

Stock Valuations

PE Ratio -44.68
PEG Ratio
Price to Book value 5.33
Price to Sales 16.45
Price to Cash Flow -34.06

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.